


GLOBAL PANDEMIC PREVENTION & BIODEFENSE CENTER

A moon shot partnership between the public and private sectors, academia, and nonprofits to ensure a global pandemic never again brings the world to the brink.



The time to invest is now.

SARS-CoV-2 has been addressed with a heroic, yet incomplete, solution set. Frontline workers were unprotected. Vulnerable populations unable to receive vaccines were unprotected. At-risk populations requiring therapies to prevent hospitalization and subsequent death were also largely unprotected. Our country requires a full arsenal of medical countermeasures, stockpiled and ready to deploy when outbreaks occur. A portfolio of human monoclonal antibodies is a necessary weapon in that arsenal – alongside diagnostics, vaccines, and other therapeutics – to provide immediate prophylactic immunity and therapy to affected communities. Science now enables us to develop stockpiles of safe and effective human monoclonal antibodies (mAbs) to fill these voids and stop outbreaks from becoming pandemics. The time to act is now to launch a public-private center to deliver mAbs as integrated solutions within the pandemic prevention life cycle.

“For the first time in our history, we have the opportunity—due to advances in science and technology— not just to refill our stockpiles, but also to transform our capabilities. However, we need to start preparing now.”

– American Pandemic Preparedness: Transforming our Capabilities (“AP3”), September 2021

The Global Pandemic Prevention and Biodefense Center (GPPBC or “the Center”) will help prevent outbreaks from becoming pandemics by developing in advance a stockpile of human monoclonal antibodies for emerging infectious diseases, and by integrating antibody development, manufacturing, distribution and delivery across the global health and pandemic prevention ecosystem.

BUSINESS MODEL

501(c)(3) organization with co-equal participation across industry, government, academia, and philanthropy.

GOVERNANCE

Independent Board supported by an Advisory Committee comprised of recognized leaders across public, private, academic, and community domains.

KEY PARTICIPANTS

Dr. James Crowe, Dr. Richard Tubb, Dr. Steve Projan, Dr. Sachiko Kuno, Honorable Andy Weber, Connected DMV, The Bill & Melinda Gates Foundation, CEPI, Bipartisan Commission on Biodefense, State of Maryland, Montgomery County, University System of Maryland, BioHealth Innovation, Maryland Technology Council, DLA Piper, and Biotech and Pharma industry leaders.

Following a comprehensive 6-month strategic planning phase (pandemicpreventionplan.org) led by renowned scientists and cross-sector experts, the Center was launched as a 501c3 non-profit organization in August 2021. The Center's flagship initiative, Advancing Human Epidemic Antibody Defenses ("AHEAD100"), will accelerate the development and delivery of monoclonal antibody (mAb) solutions as a critical medical countermeasure for both prophylactic and therapeutic use in pandemic prevention.

Through AHEAD100, the Center will coordinate across government, private sector, and civil society to provide these monoclonal antibody medical countermeasures. This program will develop and stockpile mAbs for the 100 pathogens across 15-25 pathogen families most likely to result in pandemic potential outbreaks. This aligns with AP3 goals to rapidly respond to novel threats, to advance innovations in mAb manufacturing to lower cost and accelerate delivery time, to transform regulatory pathways to better account for key innovations and advances, and to apply learnings from the COVID mAb development experience to improve the overall mAb development ecosystem.

The Center's innovative plan to build a stockpile of monoclonal antibodies will require cooperation and integration across the ecosystem, including government agencies, NGOs, philanthropic organizations, academia, and private sector entities. While funding is anticipated from philanthropic organizations, the US government must provide leadership and funding to help prevent future public health emergencies.

"Investing a modest amount annually to avert or mitigate the huge toll of future pandemics and other biological threats is an economic and moral imperative."

- American Pandemic Preparedness: Transforming our Capabilities ("AP3"), September 2021

STEERING COMMITTEE

Community & Philanthropy		Academia	Public Sector		Industry	
Biotechnology Innovation Organization (BIO) <i>Phyllis Arthur</i>	Bipartisan Commission on Biodefense <i>Dr. Asha George</i>	University System of Maryland <i>Dr. Jay Perman</i>	Director, Vaccine Research Center, Nat'l Institute for Allergies and Infectious Disease, NIH <i>Dr. John Mascola*</i>	State of Maryland <i>Secretary Kelly Schulz</i>	Moderna <i>Dr. Obadiah Plante</i>	DLA Piper <i>Hon. Jim Greenwood</i>
Brigadier Gen (ret.) White House Physician Emeritus <i>Dr. Richard Tubb</i>	Former ASD for Nuclear, Chemical, and Biological Defense <i>Hon. Andy Weber</i>	Vanderbilt University Medical Center <i>Dr. Jeff Balsler</i> <i>Dr. James Crowe</i>	Chief, Virology Branch, Nat'l Institute for Allergies and Infectious Disease, NIH <i>Dr. Cristina Cassetti*</i>	Montgomery County <i>Hon. Marc Elrich</i>	AstraZeneca <i>Dr. Mark Esser</i>	BeatTheReaper <i>Dr. Steve Projan</i>
CEPI <i>Dr. Nick Jackson</i>	World Health Organization (WHO) <i>Dr. Soumya Swaminathan*</i>	Consortium of Universities of Washington Metro Area <i>Dr. Andrew Flagel</i>	Director, Clinical Innovation, Nat'l Center for Advancing Translational Sciences, NIH <i>Dr. Mike Kurilla*</i>	Director, CBRN Countermeasures Division <i>HHS / ASPR / BARDA</i> <i>Dr. Christopher Houchens*</i>	Regeneron <i>Dr. Christos Kyrtatous</i>	Twist Bioscience <i>Dr. Emily Leproust</i>
Bill & Melinda Gates Foundation <i>Dr. Jenni Weisman</i>	S&R Foundation <i>Dr. Sachiko Kuno</i>	Boston University <i>Dr. Nahid Bhadella</i>	(Acting) Chief, Antivirals and Antitoxins <i>HHS / ASPR / BARDA / CBRN</i> <i>Dr. Karen Martins*</i>	Chief, Therapeutics Branch, Influenza and Emerging Infectious Diseases <i>HHS / ASPR / BARDA</i> <i>Dr. Kimberly Armstrong*</i>	Emergent BioSolutions <i>Dr. Laura Saward</i>	Berkeley Lights <i>Dr. Keith Breinlinger</i>
US Pharmacopeia <i>Anthony Lakavage, JD</i>	BioHealth Innovation <i>Rich Bendis</i>	Johns Hopkins University <i>In Development</i>	CMO, Nat'l Center for Immunization and Respiratory Diseases CDC <i>Dr. Amanda Cohn*</i>	Director, Medical Countermeasure Regulatory Policy, FDA <i>Elizabeth Sadove, JD*</i>	GSK <i>John Billington</i>	Kaiser Permanente <i>Ruth Williams-Brinkley</i>
Virginia Bio <i>John Newby</i>	Maryland Tech Council <i>Marty Rosendale</i>	Wellcome Leap <i>Dr. Duccio Medini</i>	Director, Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research <i>Dr. Kayvon Modjarrad*</i>	White House Office of Science & Technology Policy (OSTP) <i>In Development</i>	Children's National Hospital <i>Dr. Kalleh Eskandarian</i>	Various Biotech Companies <i>Ken Kelley</i>
Montgomery County Economic Development Corp. <i>Ben Wu</i>	Battelle National Biodefense Institute <i>Dr. George Korch</i>	Connected DMV <i>Stu Solomon</i>	JPEO-CBRND <i>In Development</i>	USAID <i>In Development</i>	eMed <i>Dr. Patrice Harris</i> <i>(Prior AMA Chair)</i>	Pinkston <i>Jim Traficant</i>

*EX-OFFICIO, NON-VOTING

FUNDING MODEL & BUDGET

\$2.5B to launch the Center and its lead initiative (AHEAD100) to be co-funded by the U.S. government, global coalitions, and philanthropy.

USE OF FUNDS

Costs to establish and staff the Center including payroll, technology, legal, and administrative support. The bulk of funds would go to a phased execution of the AHEAD100 program.

ECOSYSTEM

The ecosystem will comprise organizations and institutions from: Federal, State, and Local Government, Nonprofits, Industry, Academia, Health Care, Biotech, Defense, and Pharma.

Dr. James Crowe, Interim Board Member, Founder & Chief Scientist - AHEAD100
Stu Solomon, Interim Board Member
Ken Kelley, Interim Board Member